KRT88P and metabolic dysfunction-associated steatotic liver disease: Recently, two studies assessed OBI prevalence in patients with non-alcoholic fatty liver disease (NAFLD), one using anti-HBc as a surrogate marker and showing a prevalence of 15.5% [88] and one using the gold standard of HBV DNA detection in the liver tissues of morbidly obese patients undergoing bariatric surgery, which showed a prevalence of 12.8% [89].